Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | SORD | Q00796 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4583259 | 0.89 | JAK2 (0.48) | HCAR2MALT1HRH4HTR2CSORD | |
| SCHEMBL4583159 | 0.89 | MALT1 (0.54) | HCAR2MALT1HRH4PDGFRBDRD2 | |
| SCHEMBL4582077 | 0.89 | MALT1 (0.47) | HCAR2MALT1HRH4HTR2CSORD | |
| SCHEMBL4583985 | 0.87 | JAK2 (0.51) | HCAR2MALT1HTR2CSMN1; SMN2 | |
| SCHEMBL4584341 | 0.87 | MALT1 (0.47) | HCAR2MALT1HRH4SMN1; SMN2 | |
| SCHEMBL4583606 | 0.87 | MALT1 (0.53) | MALT1DRD2DRD4SMN1; SMN2 | |
| SCHEMBL4584132 | 0.84 | HCAR2 (0.46) | HCAR2MALT1HRH4HTR2CSORD | |
| SCHEMBL4584085 | 0.83 | MALT1 (0.49) | HCAR2MALT1HRH4HTR2CSORD | |
| SCHEMBL4581748 | 0.81 | UBE2M (0.44) | HCAR2MALT1HRH4HTR2CSORD | |
| SCHEMBL1728700 | 0.78 | HRH4 (0.54) | HCAR2MALT1HRH4HTR2CSORD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | claimed |
| EP-1903037-A1 | 1-(hetero)aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | claimed |
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | disclosed |
| EP-1903037-A1 | 1-(hetero)aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2008028690-A1 | 1-(HET)ARYL-3-[HETARYL-PIPERIDIN-4-YL]-THIOUREAS AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | PTGER2, PTGER1, PTGES2 | HCAR2 39/4885MALT1 628/4885HRH4 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.